These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 24437461)

  • 1. Clinical implications of irregular ADMET properties with levodopa and other antiparkinson's drugs.
    Dézsi L; Vécsei L
    Expert Opin Drug Metab Toxicol; 2014 Mar; 10(3):409-24. PubMed ID: 24437461
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic considerations for the use of levodopa in the treatment of Parkinson disease: focus on levodopa/carbidopa/entacapone for treatment of levodopa-associated motor complications.
    Müller T
    Clin Neuropharmacol; 2013; 36(3):84-91. PubMed ID: 23673910
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Designing prodrugs for the treatment of Parkinson's disease.
    Sozio P; Cerasa LS; Abbadessa A; Di Stefano A
    Expert Opin Drug Discov; 2012 May; 7(5):385-406. PubMed ID: 22494466
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Levodopa in Parkinson's disease: from the past to the future.
    Pezzoli G; Zini M
    Expert Opin Pharmacother; 2010 Mar; 11(4):627-35. PubMed ID: 20163273
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of integrative pharmacokinetic and pharmacodynamic optimization strategy in the management of Parkinson"s disease patients experiencing motor fluctuations with levodopa.
    Okereke CS
    J Pharm Pharm Sci; 2002; 5(2):146-61. PubMed ID: 12207867
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safinamide for the treatment of Parkinson's disease.
    Dézsi L; Vécsei L
    Expert Opin Investig Drugs; 2014 May; 23(5):729-42. PubMed ID: 24650154
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug insight: Continuous dopaminergic stimulation in the treatment of Parkinson's disease.
    Olanow CW; Obeso JA; Stocchi F
    Nat Clin Pract Neurol; 2006 Jul; 2(7):382-92. PubMed ID: 16932589
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of ageing on the pharmacokinetics of levodopa in elderly patients with Parkinson's disease.
    Nagayama H; Ueda M; Kumagai T; Tsukamoto K; Nishiyama Y; Nishimura S; Hamamoto M; Katayama Y
    Parkinsonism Relat Disord; 2011 Mar; 17(3):150-2. PubMed ID: 21172738
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Levodopa in Parkinson's Disease: Current Status and Future Developments.
    Tambasco N; Romoli M; Calabresi P
    Curr Neuropharmacol; 2018; 16(8):1239-1252. PubMed ID: 28494719
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of Parkinson's disease.
    Lieberman A
    Curr Opin Neurol Neurosurg; 1993 Jun; 6(3):339-43. PubMed ID: 8507903
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Initial therapy for Parkinson's disease: levodopa vs. dopamine receptor agonists.
    Kondo T
    J Neurol; 2002 Sep; 249 Suppl 2():II25-9. PubMed ID: 12375060
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of motor symptoms in advanced Parkinson's disease: a practical approach.
    Maranis S; Tsouli S; Konitsiotis S
    Prog Neuropsychopharmacol Biol Psychiatry; 2011 Dec; 35(8):1795-807. PubMed ID: 21645577
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Catechol-O-methyltransferase inhibition improves levodopa-associated strength increase in patients with Parkinson disease.
    Müller T; Kolf K; Ander L; Woitalla D; Muhlack S
    Clin Neuropharmacol; 2008; 31(3):134-40. PubMed ID: 18520980
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of levodopa-induced motor complications.
    Stocchi F; Tagliati M; Olanow CW
    Mov Disord; 2008; 23 Suppl 3():S599-612. PubMed ID: 18781681
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An approach to the continuous dopaminergic stimulation in Parkinson's disease.
    Schwartz M; Sabetay S
    Isr Med Assoc J; 2012 Mar; 14(3):175-9. PubMed ID: 22675859
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Rasagiline in monotherapy in patients with early stages of Parkinson's disease and in combined and adjunct therapy to levodopa with moderate and advanced stages].
    Pagonabarraga J; Rodríguez-Oroz MC
    Rev Neurol; 2013 Jan; 56(1):25-34. PubMed ID: 23250679
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety overview of FDA-approved medications for the treatment of the motor symptoms of Parkinson's disease.
    Faulkner MA
    Expert Opin Drug Saf; 2014 Aug; 13(8):1055-69. PubMed ID: 24962891
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Levodopa-carbidopa intestinal gel for treatment of advanced Parkinson's disease.
    Fernandez HH; Odin P
    Curr Med Res Opin; 2011 May; 27(5):907-19. PubMed ID: 21351823
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Myths and realities of continuous dopaminergic stimulation.
    Pirtošek Z
    Psychiatr Danub; 2011 Mar; 23(1):80-3. PubMed ID: 21448103
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intrajejunal levodopa infusion in advanced Parkinson's disease: long-term effects on motor and non-motor symptoms and impact on patient's and caregiver's quality of life.
    Fasano A; Ricciardi L; Lena F; Bentivoglio AR; Modugno N
    Eur Rev Med Pharmacol Sci; 2012 Jan; 16(1):79-89. PubMed ID: 22338551
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.